Search Result

Results for "

MLKL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (4) CDK (2) E3 Ligase Ligand-Linker Conjugates (1) Histone Methyltransferase (2) Ligands for Target Protein for PROTAC (1) Mixed Lineage Kinase (23) Necroptosis (11) PARP (1) PI3K (1) PROTACs (2) RIP kinase (12) Small Interfering RNA (siRNA) (2) Topoisomerase (1) VEGFR (2)
By Research Areas:	Cancer (20) Cardiovascular Disease (1) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141889

MLKL-IN-2	Mixed Lineage Kinase	Inflammation/Immunology
MLKL-IN-2 is a *MLKL* inhibitor extracted from patent WO2021224505A1, compound (i) .

HY-156119

MLKL-IN-6	Mixed Lineage Kinase Necroptosis	Metabolic Disease Cancer
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .

HY-156591

*PROTAC MLKL* Degrader-1**	PROTACs Mixed Lineage Kinase	Others
PROTAC MLKL Degrader-1 (Compound 36) is a PROTAC degrader of *MLKL, with a D_max* ＞90%. PROTAC MLKL Degrader-1 contains modified CRBN ligands, linker and Lenalidomide (HY-A0003)-linker fragments. PROTAC MLKL Degrader-1 abrogates cell death in a TSZ model of necroptosis.

HY-148767

MLKL-IN-5	Mixed Lineage Kinase	Others
MLKL-IN-5 is a potent *MLKL* inhibitor that mediates necroptosis .

HY-151542

MLKL-IN-4	Mixed Lineage Kinase Necroptosis RIP kinase	Neurological Disease
MLKL-IN-4 (compound 56) is a potent *MLKL* (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 82 nM . MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151541

MLKL-IN-3	Mixed Lineage Kinase Necroptosis	Neurological Disease
MLKL-IN-3 (compound 66) is a potent *MLKL* (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-3 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 31 nM . MLKL-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139878

MLKL-IN-1	Mixed Lineage Kinase	Inflammation/Immunology
MLKL-IN-1 is a covalent *MLKL* inhibitor with a K_D of 50 μM.

HY-161361

MLKL-IN-7	Mixed Lineage Kinase	Cancer
MLKL-IN-7 (compound 9) is a *MLKL* inhibitor, and shows anti-necroptosis activity in HT-29 cells with the IC₅₀ of 148.4 nM .

HY-RS08492

MLKL Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MLKL Human Pre-designed siRNA Set A contains three designed siRNAs for MLKL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLKL Human Pre-designed siRNA Set A MLKL Human Pre-designed siRNA Set A

HY-RS16563

Mlkl Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Mlkl Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mlkl gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mlkl Mouse Pre-designed siRNA Set A Mlkl Mouse Pre-designed siRNA Set A

HY-169072

*PROTAC MLKL* Degrader-2**	PROTACs Mixed Lineage Kinase	Cancer
PROTAC MLKL Degrader-2 (compound MP-1) is a PROTAC targeting *MLKL* (Mixed Lineage Kinase). PROTAC *MLKL* Degrader-2 is composed of PROTAC target protein ligand PROTAC *MLKL* Degrader-2 (HY-169072) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part) and PROTAC Linker N-Methylpiperazine (HY-78871) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074) ^{[1] ^.}

HY-144828

*RIP1/RIP3/MLKL* activator 1** 3 Publications Verification	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through *RIP1/RIP3/MLKL* pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability .

HY-162424

*ZBP1/RIP3/MLKL* activator 1**	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthetically derived quinoline compound. ZBP1/RIP3/MLKL Activator 1 induces DNA damage, enhances intracellular levels of reactive oxygen species (ROS), and triggers apoptosis via the caspase pathway. Furthermore, when apoptosis is inhibited, ZBP1/RIP3/MLKL Activator 1 promotes necroptotic cell death through the ZBP1-RIP3-MLKL pathway. ZBP1/RIP3/MLKL Activator 1 is utilized in oncological research, particularly in the selective targeting of cells with impaired apoptotic function .

HY-169074

Thalidomide-N-methylpiperazine	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-N-methylpiperazine is an E3 Ligase Ligand-Linker Conjugate. Thalidomide-N-methylpiperazine can be used to synthesize PROTAC MLKL Degrader-2 (HY-169072) to exhibit antinecroptotic activity on human cell lines and effectively degrade *MLKL* in the HT-29 xenograft mouse model .

HY-169073

TC13172-NH-COOH	Ligands for Target Protein for PROTAC	Others
TC13172-NH-COOH is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). TC13172-NH-COOH can be used for synthesis PROTAC MLKL Degrader-2 (HY-169072) .

HY-100573

Necrosulfonamide Maximum Cited Publications 93 Publications Verification	Mixed Lineage Kinase	Cancer
Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein *(MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL* is a critical substrate of RIP3 during the induction of necrosis .

HY-112292A

GW806742X hydrochloride 10+ Cited Publications	Mixed Lineage Kinase VEGFR	Cancer
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC₅₀=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis .

HY-112292

GW806742X 10+ Cited Publications	Mixed Lineage Kinase VEGFR	Others
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against VEGFR2 (IC₅₀=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis .

HY-100573S

Necrosulfonamide-d4	Mixed Lineage Kinase	Cancer
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

HY-100573A

(E/Z)-Necrosulfonamide	Mixed Lineage Kinase	Cancer
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein *(MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL* is a critical substrate of RIP3 during the induction of necrosis .

HY-101524

TC13172 2 Publications Verification	Mixed Lineage Kinase	Cancer
TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC₅₀ value of 2 nM for HT-29 cells .

HY-149393

RIPK3-IN-3	Mixed Lineage Kinase RIP kinase	Cancer
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC₅₀=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-157039

RIPK1-IN-17	RIP kinase	Inflammation/Immunology
RIPK1/3-IN-17 (Compound 10) is a RIPK1 and RIPK3 inhibitor. RIPK1/3-IN-17 specifically inhibits necroptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation .

HY-N2909

Aurantiamide	Others	Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-148365

NecroIr1	Mixed Lineage Kinase RIP kinase CDK	Cancer
NecroIr1 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and Mixed Lineage Kinase (MLKL), and regulates CDK4 expression .

HY-173185

RIP1-IN-1	RIP kinase Necroptosis	Inflammation/Immunology
RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (K_d: 110 nM). RIP1-IN-1 exhibits strong anti¬-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury .

HY-148366

NecroIr2	Mixed Lineage Kinase RIP kinase CDK	Cancer
NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression .

HY-169509

Topoisomerase I/II inhibitor 8	PARP Necroptosis Topoisomerase RIP kinase Mixed Lineage Kinase	Cancer
Topoisomerase I/II Inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of Topoisomerase I/II, capable of inducing DNA damage and PARP-1 activation, which subsequently leads to the activation of RIPK1, RIPK3, and *MLKL, ultimately triggering necroptosis. Topoisomerase I/II Inhibitor 8 demonstrates remarkable anticancer activity by effectively targeting the nuclei of cancer cells and inducing cell death through necroptosis*, showing great clinical potential in circumventing drug resistance in cancer treatment .

HY-173075

Anticancer agent 267	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and *MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC₅₀* for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models .

HY-108239

BIX-01294 trihydrochloride	Histone Methyltransferase Autophagy	Cancer
BIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells .

HY-10587

BIX-01294 20+ Cited Publications	Histone Methyltransferase Autophagy	Cancer
BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells .

HY-168640

RIP3 activator 1	Autophagy Necroptosis RIP kinase	Cancer
RIP3 activator 1 (compound C8) is a potent RIP3 activator. RIP3 activator 1 inhibits cell growth. RIP3 activator 1 induces necroptosis through the RIP3/p62/Keap1 signaling pathway. RIP3 activator 1 increases the protein expression of p-MLKL. RIP3 activator 1 induces autophagy. RIP3 activator 1 increases accumulation of LC3-II and p62 protein expression .

HY-149052

SZM-1209	RIP kinase Mixed Lineage Kinase Necroptosis	Inflammation/Immunology
SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a K_d of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC₅₀=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2909

Aurantiamide	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Source classification Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	Others
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as *RIPK3/MLKL* signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-N8380

(-)-Latifolin	Structural Classification Dalbergia hupeana Hance Source classification Phenols Polyphenols Plants Fabaceae	Apoptosis Autophagy PI3K Necroptosis
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

Cat. No.	Compare	Product Name	Species	Source

HY-P702574

	MLKL Protein, Human (His-SUMO) 1 Publications Verification hMLKL; Mixed lineage kinase domain like	Human	E. coli
	MLKL protein is a pseudokinase that plays a key role in TNF-induced necroptosis. Despite lacking intrinsic kinase activity, it is activated through RIPK3 phosphorylation, leading to homotrimerization, plasma membrane localization, and execution of necroptosis. MLKL Protein, Human (His-SUMO) is the recombinant human-derived MLKL protein, expressed by E. coli , with N-6*His labeled tag. The total length of MLKL Protein, Human (His-SUMO) is 471 a.a., with molecular weight of ~59 kDa.

Compare Products

Products

Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample
Size

Cat. No.	Product Name	Chemical Structure

HY-100573S

Necrosulfonamide-d4
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80227

	MLKL Antibody	WB, IHC-P	Human, Mouse
	MLKL Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to MLKL. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P81878

	*Phospho-MLKL* (Ser358) Antibody (YA1623)** MLKL	WB, IHC-P	Human
	Phospho-MLKL (Ser358) Antibody (YA1623) is a non-conjugated IgG antibody, targeting Phospho-MLKL (Ser358), with a predicted molecular weight of 54 kDa. Phospho-MLKL (Ser358) Antibody (YA1623) can be used for WB, IHC-P experiment in human background.

HY-P80468

	*Phospho-MLKL* (Ser345) Antibody**	WB, IHC-P	Mouse
	Phospho-MLKL (Ser345) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to Phospho-MLKL (S345). It can be used for WB,IHC-P assays with tag free, in the background of Mouse.